Skip to content
Riskpilot
← Back to search
Sign in
Sign in
Get full access
Vesiclebio AB
AB
Active
Org 5592834609
Furugatan 7, 413 21
Göteborg
Research and experimental development on natural sciences and engineering
·
NACE 7210
Est. 2020 · 5 years old
1 employees
Monitor
Share
Sweden
/
Companies
/
Research and experimental development on natural sciences and engineering
/
Vesiclebio AB
Overview
Financials
People & ownership
Related companies
Loading company…
Financials
Revenue
SEK millions
5M
4M
2M
1M
0M
2021: 2M
2M
2021
2022: 4M (+100% vs 2021)
4M
+100%
2022
2023: 2M (-50% vs 2022)
2M
-50%
2023
2024: 2M (0% vs 2023)
2M
0%
2024
2025: 1M (-50% vs 2024)
1M
-50%
2025
EBITDA
SEK millions
4M
3M
2M
1M
0M
2021: 1M
1M
2021
2022: 3M (+200% vs 2021)
3M
+200%
2022
2023: 0M (-100% vs 2022)
0M
-100%
2023
2024: 0M
0M
2024
2025: 0M
0M
2025
Income statement
SEK thousands
Item
2025
2024
2023
2022
2021
Revenue
1 321
1 624
1 742
4 109
1 654
Staff expenses
−910
−837
−1 072
−979
—
EBITDA
11
316
184
2 501
886
Depreciation & amort.
—
—
—
—
−0
EBIT
11
316
184
2 501
886
Net financials
2
2
−8
1
1
Profit before tax
13
318
124
1 877
664
Tax
−8
−74
−33
−387
−144
Net profit
5
244
92
1 490
520
Balance sheet
SEK thousands
Item
2025
2024
2023
2022
2021
Total assets
2 350
2 435
2 392
3 238
1 238
Equity
857
1 156
1 215
1 675
545
Long-term debt
—
—
—
—
0
Short-term debt
593
379
277
715
470
Total debt
593
379
277
715
470
Financial ratios
5-year trend
EBITDA margin
0,8 %
This company
15,8 %
Market median
This company
Market median
95% below market
2021
2025
Equity ratio
36,5 %
This company
38,2 %
Market median
This company
Market median
4% below market
2021
2025
Return on equity
0,5 %
This company
18,4 %
Market median
This company
Market median
97% below market
2021
2025
Net profit margin
0,3 %
This company
8,1 %
Market median
This company
Market median
96% below market
2021
2025
Asset turnover
0,56×
This company
1,12×
Market median
This company
Market median
50% below market
2021
2025
Debt / equity
1,74×
This company
0,62×
Market median
This company
Market median
181% above market
2021
2025
Annual reports & filings
Annual report 2025
Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
View
PDF
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2020-11-01 – 2021-12-31
View
PDF
More on Vesiclebio AB
Overview →
Headline figures, risk assessment and company summary
People & ownership →
Management, board and shareholder breakdown
Related companies →
Corporate hierarchy, parent and subsidiary network
